INTRODUCTION
Lung cancer is the leading cause of cancer deaths in both men and women in the USA .The incidence of lung cancer is higher in men than in women, but at present the incidence is increasing in women.
Lung cancer is expected to account for 26% of all female cancer deaths in 2011 and has been the leading cause of cancer death in women since 1987 (1) .
Smoking tobacco is the primary risk factor for lung cancer (2) (3) (4) . Heavy smoking is associated with a 20 to 30-fold increase in lung cancer risk compared to nonsmokers.
Cigarette smoking is the cause of lung cancer in %90 of cases (2) .
Squamous cell carcinomas, small cell lung carcinoma, large cell carcinoma, and to a lesser extent adenocarcinoma have an increased incidence with increased number of cigarettes smoked per day.
Radon, a radioactive gas, is the second cause of lung cancer in general population (5) , and is the main cause of lung cancer in nonsmokers. Second-hand smoke is the third leading cause of lung cancer (6, 7) .
The WHO divided lung cancer into 2 major classes:
Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Non-small cell lung cancer accounts for more than 85% of lung cancer cases and has 2 major subtypes: Squamous cell carcinoma and non squamous cell carcinoma.
In general, 30% of lung cancer cases are squamous cell carcinoma which is strongly associated with smoking.
Cavitation is more common in this type than the other types of lung cancer. About two third of squamous cell carcinomas arise within the main bronchus and lead to atelectasis and consolidation. In one third of cases, SCC can be seen in the periphery as a lung nodule or mass. 
IMAGING IN LUNG CANCER
The primary role of imaging is initial staging (8) .
Accurate staging is very important for management strategies and evaluation of prognosis. The management strategies for NSCLC and SCLC are significantly different.
In the early stages of NSCLC, surgery provides the best chance of cure either alone or in combination with chemotherapy or radiotherapy. But most patients have metastatic disease at the time of diagnosis. Small cell lung cancer initially responds well to chemotherapy and radiation and surgery should be considered only for stage I (T1-T2 N0) ( 9) . 
STAGING OF NON-SMALL CELL LUNG CANCER
Tumor staging by the TNM system provides information about the extent of disease and determines the best therapy and prognosis (11) . Resectability is the most important decision made by using TNM system. The CT evaluation of mediastinal lymph nodes has extremely variable sensitivity and specificity: %60 and 77%, respectively (13) . CT criteria for abnormal size of lymph node is more than 1cm in the short axis (14) .
Micrometastases may be seen in normal-size lymph nodes in %15 of patients with stage I, thus size alone is not a reliable criteria (15, 16) . Fatty hilum in lymph node is another morphologic sign that emphasizes its benignity (17) .
Distant metastasis (M status) is a critical factor for the resectability of a tumor. M defines tumoral involvement of distant lymph node or organs. Common sites of metastases are brain, bone, liver, adrenal glands (M1b) and contralateral lung (M1a) (18) .
The frequency of occult metastasis at the time of presentation is 30% in patients with adenocarcinoma or large cell carcinoma and 15% in squamous cell carcinoma of the lung (19) . The most common sites of distant occult metastases are adrenal gland and liver. The frequency of incidental nonfunctioning cortical adenomas is 5% in general population and in 10% of patients with lung cancer adrenal mass is seen on CT (20, 21) . If the HU of adrenal mass is less than 10 on unenhanced CT, it is considered benign. F-FDG PET is sensitive for detection of adrenal metastases. Adrenal may be the only site for metastasis but liver is never the only site except in adenocarcinoma. 
ROLE OF F-18 FDG-PET IN STAGING

FALSE-NEGATIVE AND FALSE-POSITIVE FINDINGS IN FDG-PET SCAN
DISTANT METASTASIS
There is no need for curative surgical resection in
Stage IV because of distant metastasis. An important advantage of PET-CT is the use of whole-body scanning to detect distant metastasis (Figure 3) . PET/CT is superior to standard imaging for metastasis;
however, PET/CT is inferior to MRI or CT for brain metastases (63) .
Surgery is considered for 5% of patients with stage I (T1-2 N0) SCLC in whom biopsy and pathologic staging of mediatinum is required to confirm PET/CT findings and also in patients with clinical stage T1-2, N0 disease (64) . In stage I disease, 5-year survival rate is 40%-60% (65, 66) .
PET staging changed management in 16%-38% of patients mainly due to change of radiation field because of more accurate detection of intrathoracic sites (67, 68) .
In brief, PET-CT scan can identify distant metastatic disease and may be applied to guide mediastinal evaluation, if not previously done.
CONCLUSION
One of the most important applications of FDG-PET is staging and restaging of lung cancer. PET is superior to conventional imaging modalities for detection of unsuspected mediastinal lymph node and distant metastasis. FDG-PET by accurate staging can guide the most appropriate therapy and by evaluation of therapy, reduce the morbidity and costs of ineffective treatment.
Adequate information about the limitations of FDG-PET will also provide the most accurate interpretation of PETscan.
